Safety and Efficacy Study of the Combination Daclatasvir (60 mg), Sofosbuvir (400 mg) and Ribavirin (Weight-based Dosing) for 12 or 16 Weeks in Subjects With Genotype 3 Chronic HCV Infection With or Without Prior Treatment Experience and Advanced Fibrosis or Compensated Cirrhosis

Local Institution, Darlinghurst

Local Institution, Fitzroy

Local Institution, Heidelberg

Local Institution, Clayton

Local Institution, Greenslopes

Local Institution, Adelaide

Local Institution, Grenoble

Local Institution, Vandœuvre-lès-Nancy

Local Institution, Paris

Local Institution, Créteil